Allspring Global Investments Holdings LLC Sells 1,755,412 Shares of Elanco Animal Health Incorporated $ELAN

Key Points

• Allspring Global Investments cut its Elanco stake by 62.9%, selling 1,755,412 shares in the third quarter and retaining 1,035,731 shares, valued at about $22.5 million.
• Elanco reported quarterly EPS of $0.27, beating the $0.20 consensus, while revenue of $1.26 billion topped estimates and increased 11.3% year over year. The company guided to FY 2026 EPS of $1.17–$1.20.
• Analyst sentiment is “Moderate Buy,” with an average price target of $29.75; ratings include nine Buys, two Holds, one Strong Buy, and one Sell.

Allspring Global Investments Holdings LLC trimmed its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 62.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,035,731 shares of the company's stock after selling 1,755,412 shares during the period. Allspring Global Investments Holdings LLC owned 0.21% of Elanco Animal Health worth $22,548,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. BlackRock Inc. purchased a new position in shares of Elanco Animal Health during the 2nd quarter worth approximately $1,202,198,000. Primecap Management Co. CA bought a new position in Elanco Animal Health in the second quarter worth $1,118,402,000. The Manufacturers Life Insurance Company purchased a new position in Elanco Animal Health during the second quarter valued at $205,636,000. Sei Investments Co. lifted its position in Elanco Animal Health by 737.5% during the first quarter. Sei Investments Co. now owns 5,650,393 shares of the company's stock valued at $135,214,000 after buying an additional 4,975,721 shares during the period. Finally, Bank of New York Mellon Corp purchased a new position in Elanco Animal Health during the second quarter valued at $83,958,000. Institutional investors own 97.48% of the company's stock.

Elanco Animal Health Stock Up 0.3%

Shares of Elanco Animal Health stock opened at $26.55 on Friday. The company has a 50-day simple moving average of $23.33 and a two-hundred day simple moving average of $23.87. The stock has a market capitalization of $13.27 billion, a PE ratio of -88.51, a price-to-earnings-growth ratio of 2.24 and a beta of 1.73. Elanco Animal Health Incorporated has a 52-week low of $19.40 and a 52-week high of $27.98. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 2.09.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The company reported $0.27 EPS for the quarter, beating analysts' consensus estimates of $0.20 by $0.07. The firm had revenue of $1.26 billion for the quarter, compared to analysts' expectations of $1.21 billion. Elanco Animal Health had a negative net margin of 2.86% and a positive return on equity of 8.80%. The business's revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.19 earnings per share. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. On average, analysts anticipate that Elanco Animal Health Incorporated will post 1.18 EPS for the current fiscal year.

Analyst Ratings Changes

ELAN has been the subject of a number of recent research reports. UBS Group lifted their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. The Goldman Sachs Group began coverage on shares of Elanco Animal Health in a report on Friday, October 16th. They issued a "buy" rating and a $32.00 price objective on the stock. Jefferies Financial Group downgraded shares of Elanco Animal Health from a "buy" rating to a "hold" rating and decreased their target price for the company from $31.00 to $24.00 in a research note on Tuesday, October 20th. JPMorgan Chase & Co. raised their target price on shares of Elanco Animal Health from $33.00 to $35.00 and gave the company an "overweight" rating in a research note on Monday. Finally, Morgan Stanley lowered their target price on shares of Elanco Animal Health from $26.00 to $25.00 and set an "equal weight" rating for the company in a report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Elanco Animal Health has an average rating of "Moderate Buy" and an average target price of $29.75.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, insider Shiv O'Neill bought 3,998 shares of the business's stock in a transaction on Tuesday, August 18th. The shares were acquired at an average cost of $23.58 per share, for a total transaction of $94,272.84. Following the purchase, the insider owned 87,832 shares in the company, valued at approximately $2,071,078.56. This trade represents a 4.77% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lawrence Kurzius bought 40,000 shares of Elanco Animal Health stock in a transaction on Thursday, August 20th. The stock was acquired at an average cost of $23.40 per share, with a total value of $936,000.00. Following the acquisition, the director owned 188,647 shares in the company, valued at approximately $4,414,339.80. This represents a 26.91% increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 1.14% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health. For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.